trending Market Intelligence /marketintelligence/en/news-insights/trending/YZsR9u0CiwIq-qomxG5q6w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sarepta Therapeutics' Q2 net loss widens YOY

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sarepta Therapeutics' Q2 net loss widens YOY

Sarepta Therapeutics Inc.'s non-GAAP net loss came to 83 cents per share in the second quarter, compared with the S&P Global Market Intelligence consensus normalized EPS estimate loss of 77 cents per share.

The Cambridge, Mass.-based company's loss per share was 43 cents in the year-ago period. Non-GAAP net loss widened by 118.6% to $61.2 million from $28 million in the prior-year period.

GAAP net loss increased by 152.9% from the prior-year period to $276.4 million, or $3.74 per share, from $109.3 million, or $1.67 per share.

The company noted that it recorded acquired in-process research and development expense of about $173.2 million during the second quarter related to its acquisition of gene therapy developer Myonexus Therapeutics Inc.

Sarepta said its revenues in the quarter climbed 28.8% year over year to $94.7 million from $73.5 million. The company develops RNA-based therapeutics for treating rare neuromuscular diseases.